GE Healthcare and biopharmaceutical company Dyax announced a licensing agreement to develop and commercialize peptides binding to c-Met, a growth-factor receptor.
The license includes application of the peptides in PET, SPECT, and optical imaging. GE said it will research c-Met's potential diagnostic applications and use as a patient selection biomarker in oncology, in collaboration with academic institutions and pharmaceutical companies.
